41X.F · Ardelyx, Inc

-

Please sign in to comment on 41X.F

1 Comment

Admin

4 years, 1 month ago

Ardelyx, Inc is currently in a long term uptrend where the price is trading 19.3% above its 200 day moving average.

From a valuation standpoint, the stock is 94.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 79.1.

Ardelyx, Inc's total revenue sank by 19.6% to $2M since the same quarter in the previous year.

Its net income has dropped by 45.9% to $-29M since the same quarter in the previous year.

Finally, its free cash flow fell by 60.2% to $-18M since the same quarter in the previous year.

Based on the above factors, Ardelyx, Inc gets an overall score of 2/5.

Industry	Biotechnology
ISIN	US0396971071
Exchange	F
CurrencyCode	EUR
Sector	Healthcare

Beta	0.76
Market Cap	767M
PE Ratio	None
Target Price	6.21
Dividend Yield	None

ABOUT

Ardelyx, Inc

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

41X.F · Ardelyx, Inc

-

Ardelyx, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Ardelyx, Inc using a moving average strategy